Key Takeaways:
- BioConsortia has officially closed a $15 million funding round led by long-standing internal investors, including Otter Capital
- The total internal investment in the company now stands at $95 million since its founding in 2014
- Funds will accelerate commercialization of Always-N™, a nitrogen-fixing seed treatment for industrial corn
- Investment also supports expansion of BioConsortia’s microbial discovery and development platform in Davis, California
- Always-N is positioned as a sustainable alternative to synthetic nitrogen fertilizers, with global partnerships already in place
BioConsortia Officially Closes $15M Investment Round
Funding to accelerate commercialization and platform development
BioConsortia, Inc., a leader in microbial innovation for sustainable agriculture, has officially closed a $15 million funding round. The investment was led by the company’s long-term internal investors, including Otter Capital and affiliated funds. This latest round brings the total investment from internal backers to $95 million.
“This investment, one in a series of recurring financings from our internal investors, reflects their deep confidence in BioConsortia’s science, strategy, and commercial momentum,” said Marcus Meadows-Smith, CEO of BioConsortia.
Capital to Drive Global Launch of Always-N™
Nitrogen-fixing solution aims to reduce synthetic fertilizer use
The newly secured funding will be used to scale and support the global commercialization of Always-N™, a nitrogen-fixing seed treatment for industrial corn. The product allows farmers to maintain yields while reducing dependency on synthetic nitrogen, a key contributor to greenhouse gas emissions.
Following its commercial debut in New Zealand in 2024, Always-N is now preparing for market entry in other regions, including North and South America. The product combines advanced gene editing with long shelf-life, delivering consistent field performance and environmental benefits.
“Synthetic nitrogen fertilizers are essential to modern agriculture, but their overuse comes at a steep environmental cost,” Meadows-Smith noted. “With Always-N, we offer a powerful, sustainable alternative—backed by cutting-edge science and built for real-world performance.”
Expanding Manufacturing and Market Access
Strategic global partnerships and inventory scale-up underway
The funds from the closed round will also support manufacturing expansion, inventory buildup, and broader market access for Always-N. BioConsortia is working with global partners, including The Mosaic Company, to introduce the product into key row crop markets across the Americas.
Strengthening the Discovery and Development Engine
Investment supports broader microbial pipeline development for BioConsortia
In parallel with the Always-N launch, BioConsortia will continue to invest in its proprietary discovery and development platform at its Davis, California headquarters. The platform integrates microbial selection (AMS) with gene editing (GenExpress™ and GenePro™) to develop next-generation biostimulants, fungicides, nematicides, and insecticides.
2 Comments